Controlled trial of urokinase in myocardial infarction. A European Collaborative Study.
341 patients with acute myocardial infarction have been treated in intensive or coronary care units. They were randomised into two groups, 172 receiving urokinase and 169 receiving a glucose infusion. Thereafter they were anticoagulated first with heparin and then for a year with oral anticoagulants. Despite a significantly faster regression of electrocardiographic alterations in the urokinase group there was no difference in mortality during the 1-year follow-up (29 deaths in the urokinase and 24 in the control group) and no difference in cardiac functional class between both groups.
D000328:Adult; D000368:Aged; D010450:Endopeptidases / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator